Chiasma to Present at the Cowen and Company 37th Annual Health Care Conference

WALTHAM, Mass., March 01, 2017 -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that its President and Chief Executive Officer, Mark Fitzpatrick, and SVP, Medical and Clinical Affairs, William Ludlam, will present at the Cowen and Company’s 37^th Annual Health Care Conference on Wednesday, March 8, 2017 at 8:40 a.m. ET.

A live and archived audio webcast of the presentation will be available under the News & Investors section of Chiasma’s website at www.ChiasmaPharma.com. A replay of the presentation will be available for 90 days following the conference for those unable to listen live.

About Chiasma
Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. The company is conducting an international Phase 3 clinical trial of octreotide capsules (conditionally trade-named “Mycapssa®”) for the maintenance treatment of adult acromegaly patients to support a potential submission of a Marketing Authorization Application to the European Medicines Agency. Chiasma received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on April 15, 2016 regarding its New Drug Application (NDA) for Mycapssa in the United States. Chiasma is headquartered in the United States with a wholly owned subsidiary in Israel. Mycapssa and TPE are registered trademarks of Chiasma.

Contact: 
Cammy Duong
MacDougall Biomedical Communications
(781) 591-3443
[email protected]